This highlights the fact that further research needs to be carried out into the pro‐oncogenic roles of each PDI member, focusing on key associated downstream oncogenic pathways such as UPR, to determine their potential as a therapeutic target for cancer treatment. This evidence concerns the gene P4HB and cancer.